Skip to main content

Table 1 Composition of the prostate prognosis tissue microarray. Percentage in the column “Study cohort on TMA” refers to the fraction of samples across each category. Percentage in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories

From: Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

 

No. of patients (%)

Study cohort on TMA

(n = 17,747)

Biochemical relapse among categories

Follow-up (mo)

 n

14,464 (81.5%)

3612 (25%)

 Mean

56.3

 Median

48

Age (y)

  ≤ 50

433 (2.4%)

66 (15.2%)

 51–59

4341 (24.5%)

839 (19.3%)

 60–69

9977 (56.4%)

2073 (20.8%)

  ≥ 70

2936 (16.6%)

634 (21.6%)

Pretreatment PSA (ng/ml)

  < 4

2225 (12.6%)

313 (14.1%)

 4–10

10,520 (59.6%)

1696 (16.1%)

 10–20

3662 (20.8%)

1043 (28.5%)

  > 20

1231 (7%)

545 (44.3%)

pT stage (AJCC 2002)

 pT2

11,518 (65.2%)

1212 (10.5%)

 pT3a

3842 (21.7%)

1121 (29.2%)

 pT3b

2233 (12.6%)

1213 (54.3%)

 pT4

85 (0.5%)

63 (74.1%)

Gleason grade

  ≤ 3 + 3

3570 (20.3%)

264 (7.4%)

 3 + 4

9336 (53%)

1436 (15.4%)

 3 + 4 Tert.5

798 (4.5%)

165 (20.7%)

 4 + 3

1733 (9.8%)

683 (39.4%)

 4 + 3 Tert.5

1187 (6.7%)

487 (41%)

  ≥ 4 + 4

999 (5.7%)

531 (53.2%)

pN stage

 pN0

10,636 (89.4%)

2243 (21.1%)

 pN+

1255 (10.6%)

700 (55.8%)

Surgical margin

 Negative

14,297 (80.8%)

2307 (16.1%)

 Positive

3388 (19.2%)

1304 (38.5%)

  1. Numbers do not always add up to 17,747 in the different categories because of cases with missing data. Abbreviation: AJCC American Joint Committee on Cancer